VAXCYTE, INC. Lessee, Operating Lease, Liability, to be Paid, Year Five
VAXCYTE, INC. (PCVX) had Lessee, Operating Lease, Liability, to be Paid, Year Five of $18.39 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive · last filed 2026-02-24
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $18.39M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $9.68M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $3.08M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Five |
|---|---|
| 2025-12-31 | $18.39M 10-K · filed 2026-02-24 |
| 2024-12-31 | $9.68M 10-K · filed 2025-02-25 |
| 2023-12-31 | $3.08M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |